AEON Biopharma, Inc.

General Information

We are a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. We plan to develop ABP-450 to address the estimated $2.2 billion global therapeutic botulinum toxin market, which is projected to grow to $4.4 billion in 2027. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by FDA, Health Canada and EMA. We have exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. We have built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization.  

Botulinum toxins have proven to be a highly versatile therapeutic biologic, with over 230 therapeutic uses documented in published scientific literature and 10 approved therapeutic indications in the United States. 

(Note: AEON Biopharma postponed its IPO, which was scheduled for pricing on Oct. 7, 2021, to trade on Friday, Oct. 8, 2021, “due to market conditions.”)

Employees: 6
Founded: 2012
Contact Information
Address 4040 MacArthur Blvd., Suite 260, Newport Beach, CA 92660, US
Phone Number (949) 354-6499
Web Address
View Prospectus: AEON Biopharma, Inc.
Financial Information
Market Cap $329.9mil
Revenues $1.1 mil (last 12 months)
Net Income $-53.4 mil (last 12 months)
IPO Profile
Symbol AEON
Exchange NASDAQ
Shares (millions): 5.0
Price range $14.00 - $16.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Wells Fargo Securities/ Cantor Fitzgerald
CO-Managers Mizuho Securities/ H.C. Wainwright & Co.
Expected To Trade: 10/8/2021
Status: Postponed
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change